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In mammals, targeting of newly synthesized peroxiso-
mal matrix proteins to the organelle requires Pex5p, the
peroxisomal cycling receptor. Pex5p is a multidomain
protein involved in a complex network of transient pro-
tein-protein interactions. Besides interacting directly
with most peroxisomal proteins en route to the or-
ganelle, Pex5p has also binding domains for several
components of the peroxisomal docking/translocation
machinery. However, our knowledge of how binding of a
cargo protein to Pex5p influences its properties is still
rather limited. Here, we describe a protease assay par-
ticularly useful for identifying and characterizing pro-
tein-protein interactions involving human Pex5p. Bind-
ing of a PTS1-containing peptide/protein to Pex5p as
well as the interaction of this peroxin with the Src ho-
mology domain 3 of Pex13p could be easily demon-
strated using this assay. To address the possible effects
of these Pex5p-interacting peptides/proteins on the as-
sumed quaternary structure of Pex5p, we have analyzed
the hydrodynamic properties of human Pex5p using size
exclusion chromatography, sucrose gradient centrifu-
gation, and sedimentation equilibrium centrifugation.
Our results show that Pex5p is a monomeric protein
with an abnormal shape. The implications of these find-
ings on current models of protein translocation across
the peroxisomal membrane are discussed.
Peroxisomal matrix proteins are synthesized by cytosolic
ribosomes and posttranslationally imported into the organelle.
Specific targeting of these proteins to the peroxisome is pro-
moted by one of two receptors, Pex5p or Pex7p (reviewed in
Refs. 1–4). By far the vast majority of these proteins use Pex5p
as their import receptor. Proteins belonging to this family
possess a tripeptide with the sequence SKL (or a variant) at
their C termini, the so-called peroxisomal targeting signal type
1 (PTS1)1 (5–7). The Pex5p domain involved in this interaction
is now well characterized. It comprises six TPR domains pres-
ent in the C-terminal half of the protein (6, 8–13).
PTS1-containing proteins interact with Pex5p while still in
the cytosol (reviewed in Refs. 1–4). The recognition of this
cytosolic Pex5p-cargo protein complex by the peroxisomal dock-
ing/translocation machinery is the next step in the protein
transport pathway mediated by Pex5p. Pex13p and Pex14p as
well as the RING finger peroxins Pex2p, Pex10p, and Pex12p
are components of this docking/translocation machinery (14–
16). The third step in this pathway has been the subject of
much controversy. According to some researchers, Pex5p is
translocated completely across the peroxisomal membrane to-
gether with the cargo it transports (17–19). The other perspec-
tive is that the Pex5p protein is inserted into the peroxisomal
membrane without crossing it completely. In this model, the
cargo protein-binding domain of Pex5p reaches the lumen of
the organelle where it releases the cargo protein (reviewed in
Refs. 20 and 21). Regardless of the true mechanism by which
matrix proteins are translocated across the peroxisomal mem-
brane, it is consensually accepted that Pex5p returns to the
cytosol to catalyze further rounds of transportation. This last
step (the recycling event) is probably the only one requiring
energy in the form of ATP hydrolysis (22).
The data supporting this general mechanism, the so-called
cycling receptor model, are now numerous (18, 23, 24). How-
ever, it is evident that our knowledge on many of the “details”
of this pathway is still quite poor, leaving room for controver-
sies between researchers in the field. These controversies are
not restricted to the translocation step as already stated above.
Another point of discussion regards the nature of the Pex5p
molecule(s) that interact(s) with the docking/translocation ma-
chinery. In principle, formation of a heterodimeric complex
involving a Pex5p molecule on one side and one cargo protein
on the other should suffice to ensure specific targeting of pro-
teins to the peroxisomal compartment. However, this simple
idea has been challenged by a more complex model in which
Pex5p is seen as a homotetramer and thus capable of binding
up to four PTS1-containing cargo proteins (21). Because many
peroxisomal matrix proteins are oligomers, it was proposed
that multivalent interactions would be established between
Pex5p and the proteins en route to the peroxisomal matrix,
leading to the generation of huge protein complexes. Presum-
ably, these large protein complexes would be formed at the
surface of the organelle, resulting in an increase in local con-
centration of the cargo proteins that would facilitate their
translocation across the peroxisomal membrane. More re-
cently, a refined version of this “pre-implex model” has been
proposed (25). It was suggested that in Hansenula polymorpha
cargo proteins are actually translocated across the peroxisomal
membrane by tetrameric Pex5p. After releasing the cargo pro-
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teins in the matrix of the peroxisome, Pex5p would monomerize
and return to the cytosol. Interestingly, a model in which Pex5p
also oscillates between a tetrameric and a monomeric/dimeric
form has been described recently in Leishmania donovani (26).
In this case, however, it was proposed that L. donovani Pex5p
mono- or dimerizes upon binding PTS1-containing proteins and
tetramerizes when leaving the peroxisomal compartment.
In this work, we have studied the properties of human Pex5p
when bound to a PTS1-containing peptide/protein. Data sug-
gesting the existence of PTS1-induced conformational alter-
ations on human Pex5p were obtained when in vitro synthe-
sized and recombinant Pex5p were subjected to partial
proteolysis. To determine whether binding of a PTS1-contain-
ing peptide/protein modulates in some way the assumed oligo-
meric state of human Pex5p, we have characterized the hydro-
dynamic properties of this peroxin. In agreement with previous
data, human Pex5p was found to behave as a 270-kDa globular
protein upon size exclusion chromatography (27, 28). Strik-
ingly, however, this species represents monomeric Pex5p and
not homotetramers, as assumed previously. The abnormal be-
havior of Pex5p on size exclusion chromatography is just the
result of a high frictional ratio, a property that seems to derive
from its N-terminal half. The implications of these findings for
the mechanism of protein translocation across the peroxisomal
membrane are discussed.
MATERIALS AND METHODS
Synthesis of 35S-labeled Pex5p Proteins—The cDNAs encoding full-
length human Pex5p (the large isoform; Ref. 29) or the C-terminal-
truncated version comprising amino acid residues 1–324 of Pex5p (C1-
Pex5p) preceded by the T7 RNA polymerase promotor were obtained as
described previously (30, 31). To obtain a cDNA encoding a N-terminal-
truncated version of Pex5p lacking the first 204 amino acid residues
(N204-Pex5p), the plasmid pGEM-4-Pex5 (31) was subjected to PCR
using the primers 5-gcggtcgacatggtggatgaccccaaattggcta-3 and 5-gcg-
gtcgactcactggggcaggccaaacata-3. The amplified fragment was cloned
into pGEM®-T Easy Vector according to the manufacturer’s instruc-
tions (Promega). The recombinant plasmid was digested with SalI, the
insert was cloned into the SalI site of pGEM-4 (Promega), and the
resulting plasmid was linearized by cutting it with NheI. These Pex5p-
encoding DNAs were subjected to in vitro transcription using T7 RNA
polymerase (Roche Applied Science). 35S-labeled proteins were synthe-
sized using the translation kit Retic Lysate IVTTM (Ambion) in the
presence of RedivueTM L-[35S]methionine (specific activity 1000 Ci/
mmol) following the manufacturer’s instructions.
Recombinant Proteins—For expression of the fusion protein His6-
PEX5p, the plasmid pGEM-4-Pex5 (31) was used as template in a PCR
reaction using the forward primer 5-ccggcatgcgcaatgcgggagctggtgg-3
and the reverse primer 5-gcggtcgactcactggggcaggccaaacat-3. The am-
plified DNA fragment was cloned into pGEM®-T Easy Vector according
to the manufacturer’s instructions (Promega). The recombinant plas-
mid was digested with SphI and SalI, and the insert was cloned into
pQE-30 (Qiagen), resulting in the pQE-Pex5 plasmid. Expression was
performed in the M15 strain of Escherichia coli. 100-ml cultures were
induced with 1 mM isopropyl 1-thio--D-galactopyranoside for 2 h at
37 °C. Pelleted cells were cooled on ice and lysed by sonication in 1.5 ml
of 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% (w/v) Triton X-100, 1 mM
EDTA-NaOH, pH 8.0, 1 mM DTT, 0.1 mg/ml phenylmethylsulfonyl
fluoride, and 1:500 (v/v) mammalian protease inhibitor mixture
(Sigma). Cell debris were removed by centrifugation (15 min at
10,000  g), and the clarified supernatant was incubated with 100 l
(bed volume) of HIS-SelectTM nickel affinity gel (Sigma) for 2 h at 4 °C.
The gel was washed three times with 1.5 ml of 50 mM sodium phos-
phate, pH 8.0, 150 mM NaCl, and the His6-PEX5p was eluted by wash-
ing the beads three times with 600 l of 50 mM sodium phosphate, pH
8.0, 150 mM NaCl, 50 mM imidazole. The eluted protein was concen-
trated to 50 l using a Vivaspin 10,000 MWCO PES concentrator
(Vivascience), diluted to 600 l with 50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 1 mM EDTA-NaOH, pH 8.0, 1 mM DTT, and concentrated again.
This procedure was repeated two more times. Aliquots of the His6-
PEX5p recombinant protein were frozen in liquid nitrogen and stored at
70 °C.
To test whether the introduction of this purification tag at the N
terminus of human Pex5p interferes with its function, the plasmid
pQE-Pex5 was subjected to an expression PCR protocol (32). In the first
PCR the upper primer 5-gggagagccaccatgagaggatcgcatcac-3 and the
lower primer 5-gcgtaattaagcttggctgcaggtc-3 were used. In the second
PCR the same lower primer was used together with the primer 5-
gaattctaatacgactcactatagggagagccaccatg-3. The amplified fragment
was subjected to in vitro transcription/translation as described above,
and the 35S-labeled His6-tagged Pex5p was used in in vitro import
experiments exactly as described before (23). These experiments re-
vealed that His6-tagged Pex5p is inserted into the peroxisomal mem-
brane originating Stage 2 Pex5p (when ATP was included in the import
reactions) or Stage 2 plus Stage 3 Pex5p (when ATPS was used).
Furthermore, addition of a GST fusion protein containing the TPR
domains of Pex5p to the import medium blocked the insertion of this
His6-tagged protein into the organelle membrane (data not shown), as
described previously for the untagged human Pex5p (see Refs. 23 and
30). These data suggest that the modified N terminus does not inacti-
vate Pex5p. The synthesis and purification of GST-LKS (GST ending
with a nonfunctional PTS1-like sequence), GST-SKL (GST containing a
PTS1 signal at the C terminus), and the histidine-tagged SH3 domain
of human Pex13p (amino acid residues 236–403; Pex13p-SH3) were
described before (30, 33).
Protease Assay—Protease treatment of Pex5p was performed in
buffer A (50 l of 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA,
and 1 mM DTT). One l of the reticulocyte lysates containing the
35S-labeled Pex5p proteins or 5 g of His6-PEX5p recombinant protein
were used per reaction. Peptides (see below) and GST-LKS or GST-SKL
were added to 2 M final concentration. Pex13p-SH3 was used at a final
concentration of 1.5 M. After 10 min at 37 °C, the samples were placed
on ice and treated for 15 min with 0.5 g/ml (for radioactive proteins) or
1 g/ml (for recombinant Pex5p) of proteinase K. The protease was
inactivated with phenylmethylsulfonyl fluoride (0.5 mg/ml), and the
proteins were precipitated with trichloroacetic acid (10% (w/v)), washed
with acetone, and analyzed by SDS-PAGE.
Sucrose Gradient Centrifugation—20 g of recombinant Pex5p or 3
l of the reticulocyte lysates containing radioactive Pex5p or C1-
Pex5p were incubated in 200 l of buffer A in the presence of 2 M
GST-LKS or GST-SKL for 10 min at 37 °C. Trace amounts (2 g) of
bovine IgGs (6.9 s), bovine serum albumin (4.3 s), soybean trypsin
inhibitor (2.3 s), and cytochrome c (1.9 s) were added to the samples as
internal standards (numbers in parenthesis represent the sedimenta-
tion coefficients). These mixtures were then applied onto the top of a
discontinuous sucrose gradient (2.0 ml of 4%, 1.8 ml of 8%, 1.7 ml of
12%, 1.5 ml of 16%, 1.2 ml of 20%, 1 ml of 25%, and 1 ml of 30% (w/v)
sucrose in buffer A supplemented with 2 M GST-LKS or GST-SKL.
After centrifugation at 38,000 rpm for 20 h at 4 °C in a TST41.14
swing-out rotor (Sorvall), 13 fractions of 0.8 ml were collected from the
bottom of the tube and analyzed by SDS-PAGE. The sedimentation
coefficients of the Pex5p proteins were estimated by interpolation from
the linear plots of the s values of the standard proteins versus their
gradient fractionation volume.
Size Exclusion Chromatography—Human Pex5p recombinant pro-
tein (20 g of protein) or in vitro synthesized proteins (1 l of the
corresponding reticulocyte lysates) were incubated in 200 l of buffer A
containing 40 M peptides (see below) or 10 M GST-SKL or GST-LKS
for 10 min at 37 °C. Protein samples were injected into a Superose 12
HR 10/30 column (Amersham Biosciences) running with 50 mM Tris-
HCl, pH 7.5, 0.15 M NaCl, 1 mM EDTA-NaOH, pH 7.5, at 0.5 ml/min.
The inclusion of 1 mM DTT in this running buffer did not change the
elution profile of the Pex5p proteins (see Ref. 28; data not shown). The
column was calibrated with the following standards (numbers in pa-
renthesis represent the Stokes radii): thyroglobulin (8.5 nm), ferritin
(6.1 nm), aldolase (4.8 nm), bovine serum albumin (3.6 nm), and soy-
bean trypsin inhibitor (2.3 nm). Fractions of 500 l covering the rele-
vant Stokes radius range were always collected, subjected to trichloro-
acetic acid precipitation, and analyzed by SDS-PAGE. In some
experiments with the recombinant protein the A280 profile of the chro-
matography revealed the existence of one or two extra protein peaks
(corresponding to globular proteins with molecular masses of 130 and
60 kDa) in addition to the “270 kDa” species. Analysis of the correspond-
ing SDS gels showed that only the “270 kDa” peak correlated with
His-tagged Pex5p; the other peaks were due to the presence of Pex5p
proteolytic fragments (data not shown). These Pex5p preparations were
discarded. The Stokes radii of the Pex5p proteins were determined as
described (34).
Sedimentation Equilibrium Centrifugation—Recombinant Pex5p
(200 g) was subjected to size exclusion chromatography as described
above. Fractions containing the “270-kDa” protein peak were pooled
and concentrated to 1 mg/ml using a Vivaspin 10,000 MWCO PES
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concentrator (Vivascience). Sedimentation equilibrium analysis was
performed at the National Centre for Macromolecular Hydrodynamics
at the University of Nottingham (UK) using a Beckman XL-A analytical
ultracentrifuge equipped with scanning absorption optics.
The same analysis was performed using a different version of human
Pex5p recombinant protein purified as described before (28). In this
protein there is a tobacco etch virus protease cleavage site between the
N-terminal His tag and the Pex5p sequence. Sedimentation equilibrium
analysis of this recombinant protein (0.4 mg/ml in 20 mM Tris-HCl, pH
8.0, 150 mM NaCl, 15 mM MgCl2, 1 mM DTT) was performed in a
Beckman XL-A analytical ultracentrifuge at European Molecular Biol-
ogy Laboratory, Heidelberg, Germany.
Miscellaneous—Molecular masses of native proteins (M) and fric-
tional ratios (f/fo) were calculated from their Stokes radii and sedimen-
tation coefficients as described in Ref. 35 using Equations 1 and 2
M  6Nas/(1  v) (Eq. 1)
and
f/fo  a/(3vM/4N)1/3 (Eq. 2)
where  is the viscosity of the medium, N is the Avogadro’s number, a
is the Stokes radius, s is the sedimentation coefficient, v is the partial
specific volume of the protein, and  is the density of the medium.
Partial specific volumes for Pex5p proteins and GST-SKL were cal-
culated using the program SEDNTERP v1.08 (www.jphilo.mailway-
.com/default.htm). Edman degradation of Pex5p proteolytic fragments
was performed by HHMI/Keck Biotechnology Resource Laboratory
(New Haven, CT). The peptides CRYHLKPLQSKL (Pep-SKL) and
CRYHLKPLQLKS (Pep-LKS) were synthesized by Sigma Genosys. The
peptide YQSKL was a kind gift from Dr. W. Nastainczyk, University of
Saarland, Germany.
RESULTS
Controlled digestion of a protein using proteases may reveal
important insights on its structure. In many cases, such assays
can even be used to characterize ligand-induced conformational
alterations on the protein being studied (e.g. Ref. 36). Natu-
rally, such strategy can also be applied to the identification of
putative ligands of a given protein even if the ligands being
tested are proteins themselves. In this case, however, positive
results may only be obtained if the protein under study is much
more sensitive to the protease than the ligands added to the
assay, something that can be easily determined empirically.
Using this rationale we have developed a simple procedure to
identify and characterize protein-protein interactions involving
human Pex5p. As shown below, because of its high sensitivity
to proteases (see also Ref. 37) Pex5p is a suitable protein to use
in this kind of assay. The procedure consists of incubating
human Pex5p (obtained either from in vitro transcription/
translation reactions or from heterologous expression in E. coli)
with the test proteins/peptides, followed by limited proteolysis
with proteinase K (see “Materials and Methods” for details).
Binding of a PTS1-containing Peptide/Protein to Human
Pex5p Changes the Accessibility of Proteinase K to a Region of
the Pex5p Protein That Precedes Its PTS1-binding Do-
main—We started our analysis by characterizing the interac-
tion of Pex5p with PTS1-containing proteins/peptides. In vitro
synthesized 35S-Pex5p was incubated with either a PTS1-con-
taining peptide (pep-SKL) or with a negative control peptide
(pep-LKS; see “Materials and Methods”) and subjected to treat-
ment with a very low concentration (0.5 g/ml) of proteinase K.
After inactivation of the protease the samples were analyzed by
SDS-PAGE and autoradiography. As shown in Fig. 1A, lanes 1
and 2, different proteolytic patterns are observed suggesting
that Pex5p bound to pep-SKL displays a different susceptibility
to proteinase K. The most evident differences regard the ap-
pearance of a 40-kDa doublet protein band when pep-SKL is
used in these experiments and a 35-kDa protein band that is
particularly abundant when the control peptide is used. The
40-kDa doublet band was also observed when a shorter PTS1-
containg peptide (YQSKL) was used in these experiments (data
not shown). Exactly the same results were obtained when GST-
SKL and GST-LKS were substituted for pep-SKL and pep-LKS,
respectively (Fig. 1A, lanes 3 and 4).
To characterize the Pex5p-derived fragments described
above, we repeated the protease assay but this time using
chemical amounts of recombinant human Pex5p. The results
presented in Fig. 1B demonstrate that recombinant Pex5p dis-
plays the behavior of the in vitro synthesized peroxin. N-ter-
minal sequencing of the 40-kDa doublet protein band gener-
ated a mixture of two peptide sequences, as expected (for
practical reasons, no efforts were made to resolve the two
protein bands in order to obtain independent sequences). The
sequences were easily ascribed to amino acid residues 291–296
and 295–300 of human Pex5p. Edman degradation of the 35-
kDa protein band also resulted in a mixture of two peptide
sequences, indicating the presence in this band of two Pex5p
fragments that probably also differ at their C termini. One of
these fragments starts with the sequence WLSDYD (residues
308–313) and the other with TYDKDG (residues 319–324) of
human Pex5p. Taken together these data indicate that binding
of a PTS1-containing peptide/protein to Pex5p changes the
accessibility of proteinase K to peptide bonds linking amino
acid resides 307–308 and 318–319 of human Pex5p. These
amino acid residues precede the first TPR domain of human
Pex5p (11) by 30 and 19 amino acid residues, respectively.
Characterization of the Pex5p-Pex13p Interaction—Pex13p is
a component of the peroxisomal docking/translocation machin-
ery that contains a C-terminal SH3 domain facing the cytosolic
side of the peroxisomal membrane (reviewed in Refs. 1–4). It
has been demonstrated that Pex5p from lower eukaryotes in-
teracts directly with the SH3 domain of Pex13p (38–41). In
mammals, however, this subject has remained obscure. First,
using yeast two-hybrid technology both positive and negative
results have been described for this pair of proteins (39, 42).
Second and most importantly, all attempts to detect the exist-
ence of a direct interaction between mammalian Pex5p and the
SH3 domain of Pex13p using several in vitro assays have failed
FIG. 1. Binding of a PTS1-containing peptide/protein to Pex5p
changes its proteolytic profile. A, in vitro synthesized Pex5p was
incubated in the presence of pep-LKS (lane 1), pep-SKL (lane 2), GST-
LKS (lane 3), or GST-SKL (lane 4) for 10 min at 37 °C. After treatment
with proteinase K (see “Materials and Methods”) the samples were
analyzed by SDS-PAGE and autoradiography. The 40- and the 35-kDa
bands are indicated by arrows a and b, respectively. Lane Ly, 0.5 l of
the Pex5p-containing reticulocyte lysate. Numbers at left side indicate
the molecular mass of the protein markers. B, recombinant Pex5p was
incubated in the presence of either pep-LKS (lane 2) or pep-SKL (lane
3) and subjected to treatment with proteinase K. A Coomassie blue-
stained gel is shown. Arrows a and b indicate the 40- and 35-kDa
protein bands, respectively. Lane 1, untreated recombinant protein (2
g). M, molecular mass standards as shown in panel A.
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(33, 43). It should be emphasized that mammalian Pex5p does
interact with the complete version of Pex13p, as demonstrated
recently by pulldown experiments (43). Interestingly, the
Pex5p domain mapped in those experiments corresponds to the
SH3-binding domain of Pex5p from lower eukaryotes. How-
ever, when GST fusion proteins containing different domains of
Pex13p were applied to these assays positive results were only
obtained with a recombinant protein comprising amino acid
residues 1–135 of human Pex13p (43).
As an attempt to clarify this issue, two GST fusion proteins
containing either amino acid residues 1–135 or 255–403 of
human Pex13p were produced and used in our protease assay.
In both cases, negative results were obtained (data not shown).
Obviously, as stated above, negative results in this assay may
result from the fact that the ligands being tested are particu-
larly sensitive to the protease. Nevertheless, the possibility
that the presence of a GST moiety at the N terminus of the SH3
domain of Pex13p interferes with the binding of this fusion
protein to Pex5p was still considered. Thus, an N-terminal
histidine-tagged version of the SH3 domain of human Pex13p
(Pex13-SH3) was used in these assays. As shown in Fig. 2,
proteinase K treatment of 35S-Pex5p preincubated with Pex13-
SH3 results in major differences in the proteolytic pattern of
Pex5p. Interestingly, the degree of Pex13-SH3-induced protec-
tion is particularly evident in the absence of PTS1-containing
peptide (compare lanes 5 and 6), corroborating the idea that
Pex13p binds with a higher affinity to free Pex5p than to cargo
protein-loaded Pex5p (40, 43). To verify the specificity of the
observed interaction, we included in these experiments a trun-
cated version of Pex5p lacking amino acid residues 1–204
(N204-Pex5p). This protein lacks the Pex13p-interacting do-
main defined previously (43) but is still functional in binding
the PTS1-containing peptide (compare lanes 3 and 4 with lanes
7 and 8). No Pex13-SH3-induced protection effect was observed
in this case (lanes 9 and 10). We conclude that the SH3 domain
of human Pex13p interacts specifically with Pex5p and thus
that the type of interaction between these two peroxins was
conserved during evolution.
Human Pex5p Is a Monomeric Protein—Considering the
growing number of reports claiming that Pex5p from several
organisms oscillates between a tetrameric and a monomeric
state (see “Discussion”), the protein-protein interactions de-
scribed above cannot be rationalized in a simple way. For
instance, the observed effect of a PTS1-containing peptide/
protein upon the sensitivity of human Pex5p to proteinase K
could simply result from a change in the quaternary struc-
ture of Pex5p, as suggested recently for Pex5p from L. dono-
vani (26). To clarify this issue we have determined the mo-
lecular mass of the Pex5p proteins used in this work. Two
different approaches were used. In the first, we used the
strategy developed by Siegel and Monty (35). In this method
the sedimentation coefficient (determined by sucrose gradi-
ent centrifugation analysis) and the Stokes radius of a pro-
tein (determined by size exclusion chromatography) are used
to calculate its molecular mass. In the second, we used equi-
librium sedimentation analysis. Here, the molecular mass of
a protein is determined directly and is a function of both its
sedimentation and diffusion coefficients.
We started these studies by determining the sedimentation
coefficient of human Pex5p. Particular attention was given to
the resolution properties of the sucrose gradients; protein sam-
ples in a small volume (200 l) were carefully applied onto the
top of the gradients. GST-SKL or the corresponding negative
control, GST-LKS, was included in the sucrose solutions (2 M
each) used to make the gradients. In each experiment, two
sucrose gradients were run in parallel. One, containing GST-
SKL, was loaded with Pex5p preincubated with GST-SKL; the
other, containing GST-LKS, received the same amount of
Pex5p preincubated with GST-LKS.
The results obtained with recombinant human Pex5p are
shown in Fig. 3A. In the absence of a PTS1-containing protein
(“plus GST-LKS” conditions), recombinant Pex5p (predicted
molecular mass of 72.3 kDa) behaves as a 40-kDa globular
protein (sedimentation coefficient of 3.68  0.18 s), sediment-
ing well above bovine serum albumin (MW 66.2; sedimentation
coefficient of 4.31 s). This abnormal sedimentation behavior
indicates that Pex5p is not a globular/spherical protein. A
different sedimentation coefficient is observed when this anal-
ysis is performed in the presence of GST-SKL. Under these
conditions, Pex5p behaves as a 90-kDa globular protein (sedi-
mentation coefficient of 5.0  0.27 s), sedimenting slightly
below albumin, indicating that Pex5p formed a complex with
GST-SKL. It is important to note that the vast majority of the
recombinant Pex5p protein displays this behavior, indicating
the absence of significant amounts of misfolded Pex5p in our
protein preparations.
The sedimentation properties of in vitro synthesized human
Pex5p were also analyzed. In the experiment described here, a
truncated version of human Pex5p (C1-Pex5p) that lacks the
PTS1-binding domain of the peroxin was also included as a
negative control. As shown in Fig. 3B, in vitro synthesized
Pex5p displays the sedimentation properties of the recombi-
nant protein: an increase in the sedimentation coefficient is
observed when GST-SKL is used in these experiments. As
expected, the sedimentation behavior of C1-Pex5p is the same
independent of the GST fusion protein used in these analyses.
In the presence of GST-SKL or GST-LKS, C1-Pex5p (pre-
dicted molecular mass of 37.1 kDa) was found to sediment
together with soybean trypsin inhibitor, displaying a sedimen-
tation coefficient of 2.4  0.13 s.
We next subjected these Pex5p proteins to gel filtration chro-
matography. The results obtained with the recombinant pro-
tein are shown in Fig. 4A. Pex5p preincubated with GST-LKS
or pep-LKS elutes from the column after ferritin (MW 440;
Stokes radius of 6.1 nm) and before aldolase (MW 158; Stokes
radius of 4.8 nm). A Stokes radius of 5.33  0.21 nm was
estimated for this recombinant protein. Basically the same
value is obtained when Pex5p is preincubated with pep-SKL. In
contrast, when Pex5p is incubated with GST-SKL prior to
chromatography, a small decrease in the elution volume of the
recombinant protein is observed, suggesting that a Pex5p-GST-
SKL complex was formed and resisted the separation proce-
FIG. 2. Proteolytic profiles of Pex5p in the presence of Pex13-
SH3. In vitro synthesized Pex5p (lanes 3–6) or N204-Pex5p (lanes
7–10) were incubated with either pep-LKS (lane 3, 5, 7, and 9) or
pep-SKL (lanes 4, 6, 8, and 10) in the absence (lanes 3, 4, 7, and 8) or
presence of Pex13-SH3 (lanes 5, 6, 9, and 10). After proteinase K
treatment, the samples were analyzed by SDS-PAGE and autoradiog-
raphy. Lanes 1 and 2, reticulocyte lysates containing human Pex5p and
N204-Pex5p, respectively. In vitro synthesis of N204-Pex5p results
in two major products. The faster migrating band is probably the result
of translation initiation at an internal ATG. Numbers at left side
indicate the molecular mass of the protein markers.
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dure. SDS-PAGE analysis of the chromatography fractions con-
firmed this interpretation (see Fig. 4B). A stoke radius of
5.86  0.31 nm was estimated for this protein complex.
Analysis of 35S-labeled Pex5p by size exclusion chromatog-
raphy revealed essentially the same behavior. Preincubation of
the 35S-labeled Pex5p with either pep-SKL or pep-LKS does not
change the elution profile of the in vitro synthesized protein. In
both cases a behavior similar to the one displayed by the
recombinant protein is observed (data not shown). The same
result is obtained when the in vitro synthesized protein is
preincubated with GST-LKS before being subjected to chroma-
tography (Fig. 4C). In contrast, preincubation of 35S-labeled
Pex5 with GST-SKL leads to a small decrease in the elution
volume of the radioactive protein. Interestingly, C1-Pex5p
elutes from the column immediately after Pex5p. As expected,
the behavior of this truncated protein remains unchanged re-
gardless of the GST fusion protein used in the preincubation
step. A Stokes radius of 5  0.25 nm was estimated for
C1-Pex5p.
Having determined the sedimentation coefficients and the
Stokes radii for these Pex5p proteins, we calculated their mo-
lecular masses using Equation 1 (see “Materials and Meth-
ods”). Values of 80.5  4.9, 48.3  3.6, and 124.1  9.4 kDa
were obtained for Pex5p, C1-Pex5p, and the Pex5p-GST-SKL
protein complex, respectively. We have also determined the
frictional ratios (see Equation 2 under “Materials and Meth-
ods”) for human Pex5p and its N-terminal half, C1-Pex5p.
Values of 1.94  0.08 and 2.28  0.12, respectively, were
obtained. Thus, human Pex5p is a monomeric protein with an
abnormal shape, a property that seems to stem from the con-
formation of its N-terminal half (see “Discussion”).
Exactly the same conclusion regarding the molecular mass of
recombinant human Pex5p was obtained upon sedimentation
equilibrium centrifugation analysis. It is important to note that
in this technique the protein under analysis is neither diluted
(quite the opposite) nor subjected to high hydrostatic pressures.
The experimental molecular mass determined for this protein
was 73.8  2.6 kDa, a value in perfect agreement with its
predicted molecular mass (72.3 kDa). No evidence for the ex-
istence of dimers, tetramers, or higher order oligomers could be
found in this experiment.
This analysis was also performed with a different Pex5p
recombinant protein produced and purified as described else-
where (28). In this case a molecular mass of 73.3 1.0 kDa was
determined. Again, no evidence for the existence of Pex5p oli-
gomers could be found in this analysis. In summary, these
results indicate that human Pex5p is a monomeric protein and
remains in a monomeric state when bound to a PTS1-contain-
ing protein.
DISCUSSION
Over the last years a number of reports have been published
stating that recombinant Pex5p from several organisms is a
tetrameric protein (25–28). These conclusions have been used
to develop and support the so-called pre-implex model (21).
According to this hypothesis, tetrameric Pex5p would bind up
to four PTS1-containing proteins. Because many of these cargo
proteins are themselves oligomers, it was proposed that large
Pex5p-cargo protein complexes would be formed at the peroxi-
somal membrane. This phenomenon would create a high local
concentration of peroxisomal proteins at the outer surface of
the organelle membrane, which in turn could facilitate protein
translocation across the peroxisomal membrane.
The propensity of recombinant human Pex5p to originate
aggregates is a well known property of this protein (27, 28).
Indeed, incubation of recombinant human Pex5p in low ionic
strength buffers (28) or the isolation of this protein in the
absence of reducing agents can lead to heterogeneous (oligo-
FIG. 3. Sucrose gradient sedimentation analysis of Pex5p. A,
recombinant human Pex5p was preincubated with either GST-LKS
(upper panel) or GST-SKL (lower panel). A mixture of proteins with
known sedimentation coefficients was added to both samples before
applying them onto the top of the sucrose gradients containing either
GST-LKS (upper panel) or GST-SKL (lower panel). After centrifugation,
fractions were collected from the bottom of the tube and analyzed by
SDS-PAGE. Pex5p, the GST fusion proteins, and the sedimentation
standards are indicated by arrows. The internal sedimentation stand-
ards used were: cytochrome c (Cytc), soybean trypsin inhibitor (STI),
bovine serum albumin (BSA), and immunoglobulins (IgG). Only the
heavy chains of IgGs are visible in the gels; the light chains, which
co-sediment with the heavy chains, are partially masked by the GST
fusion proteins. The asterisk indicates two protein bands present in
some preparations of recombinant Pex5p. Considering that these two
polypeptides are recognized by an anti-Pex5p antibody (data not shown)
and that they were purified exploring the presence of a N-terminal
histidine tag, they probably represent C-terminal-truncated Pex5p mol-
ecules. The similarity between their sedimentation behavior and the
one displayed by C1-Pex5p (see panel B) is evident. Molecular mass
standards (from top to bottom): 97.4, 66.2, 45.0, 31.0, 21.5, 14.4 kDa. B,
in vitro synthesized Pex5p and C1-Pex5p were preincubated with
either GST-LKS (upper panel) or GST-SKL (lower panel). A small
amount of sedimentation standards (see above) was added to both
samples. The mixtures were loaded onto the top of the sucrose gradients
containing either GST-LKS (upper panel) or GST-SKL (lower panel).
After centrifugation, fractions were subjected to SDS-PAGE, blotted
onto a nitrocellulose membrane, and exposed to an x-ray film. The
internal sedimentation standards (indicated at the bottom of the figure)
were visualized on the Ponceau S-stained membrane.
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meric) protein preparations.2 Obviously, these are not the type
of Pex5p-Pex5p interactions residing at the base of the pre-
implex model. The model explicitly assumes the existence of
biologically relevant Pex5p tetramers. What is the experimen-
tal evidence behind this premise? One of the first observations
suggesting that Pex5p could be a tetramer of identical subunits
was obtained when negatively stained recombinant human
Pex5p preparations were analyzed by electron microscopy (28).
Those studies revealed the existence of square-shaped particles
with approximate dimensions of 13  13 nm. The data pre-
sented in this work do not provide any clues regarding the
nature and origin of these square-shaped particles. However,
they do indicate that these particles do not represent the Pex5p
protein as it exists in solution: as shown here, Pex5p is a
monomeric protein.
The assumption that Pex5p is a spherical protein has also
been made by researchers, one of us included, trying to infer
the molecular mass of recombinant Pex5p using size exclusion
chromatography (26–28). In this context, the results available
for Pex5p from L. donovani are particularly interesting. This
protein also displays an abnormal behavior upon size exclusion
chromatography, an observation that led to the conclusion that
Pex5p from this organism is a tetramer (44). However, as
emphasized in a later work, binding assays using a PTS1-
containing peptide failed to demonstrate the existence of those
tetramers (26). Instead, the binding data reported were com-
patible with the existence of a monomeric Pex5p population.
Thus, it was hypothesized that binding of PTS1-containing
proteins to L. donovani Pex5p results in its monomerization
(26). If the data described here for human Pex5p are extrapo-
lated to the L. donovani protein, then these conflicting results
have a simple explanation: L. donovani Pex5p is a monomeric
protein with an asymmetric shape. It should be noted that the
2 J. Costa-Rodrigues, A. F. Carvalho, C. Sa´-Miranda, and J. E.
Azevedo, unpublished results.
FIG. 4. Size exclusion chromatography of human Pex5p. A, recombinant Pex5p was preincubated with either pep-SKL (black line) or
pep-LKS (gray line) and analyzed by size exclusion chromatography (upper panel). The same analysis was performed with recombinant Pex5p
preincubated with either GST-SKL (black line) or GST-LKS (gray line). The corresponding chromatograms are shown in the lower panel. Numbers
at the top of the chromatogram (lower panel) indicate the fractions collected and analyzed by SDS-PAGE. The Coomassie Blue-stained gels are
shown in panel B. The asterisks indicate three E. coli contaminating proteins present in this GST-LKS preparation. C, in vitro synthesized human
Pex5p or C1-Pex5p was incubated with either GST-LKS or GST-SKL and analyzed by size exclusion chromatography. Collected fractions were
subjected to SDS-PAGE and analyzed by autoradiography. The void volume (a) and the elution volumes of tyroglobulin (b), ferritin (c), aldolase (d),
bovine serum albumin (e), and soybean trypsin inhibitor (f) are indicated.
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similarities between the experimental results described for
these two Pex5p proteins are not limited to the behavior of the
full-length versions upon size exclusion chromatography. The
results regarding the N-terminal halves of the two Pex5p pro-
teins are also in perfect agreement with each other. Our con-
clusion is that the N-terminal half of human Pex5p is a mono-
meric protein displaying a high frictional ratio. The conclusion
regarding the N-terminal domain of L. donovani Pex5p was
that it adopts a hexameric structure (26).
Finally, similar observations regarding the tetrameric na-
ture of H. polymorpha Pex5p have also been described. The
authors inferred the molecular mass of Pex5p from the diffu-
sion constant of the protein at pH 7.2, as determined by fluo-
rescence correlation spectroscopy (25). Again, the premise used
to calculate the molecular mass of H. polymorpha Pex5p was
that the protein is spherical in shape. The data presented here
for the human peroxin strongly suggest that this may not be
the case. Interestingly, the hydrodynamic data described by the
same group for a Pex5p-Pex8p protein complex at pH 7.2 are
compatible with the existence of a heterodimeric protein com-
plex displaying a globular shape (25). Based on our data we
would propose that upon binding Pex8p, H. polymorpha Pex5p
suffers large conformational alterations. Determination of the
sedimentation coefficients for H. polymorpha Pex5p alone and
in the presence of Pex8p should clarify this issue.
All considered, we have to admit that the experimental evi-
dence supporting the existence of a tetrameric Pex5p and thus
of the pre-implex model is, at the very least, questionable. The
data described here for the human protein are clearly not
compatible with such a model.
The high frictional ratio observed for the N-terminal half of
Pex5p indicates that this domain does not adopt a globular
folding. Thus, it is likely that this Pex5p domain adopts an
extended conformation and/or is natively unfolded (see Ref. 45
for a review on natively unfolded domains). The resolution of
this issue will require biophysical data regarding the structure
of this Pex5p domain.
The hydrodynamic properties of the N-terminal domain of
Pex5p are in contrast with the characteristics of the C-terminal
half of Pex5p. Indeed, all the available data indicate that this
domain displays “normal” hydrodynamic properties as can also
be predicted by the tridimensional structure of the human TPR
domains (11, 28, 44). Considering the high frictional ratio of
human Pex5p observed in this work, it is thus evident that the
N-terminal domain of Pex5p dominates the hydrodynamic
properties of the full-length protein. This domain structure
explains why relatively small deletions at the N-terminal half
of Pex5p can result in dramatic alterations of its Stokes radius
as observed by size exclusion chromatography (Ref. 26).2
How are the C- and N-terminal halves oriented to each
other? The fact that the Stokes radius of C1-Pex5p is almost
similar to the one displayed by the full-length protein could
suggest that the two halves of the protein interact laterally and
not in a head-to-head configuration. Although such a structural
model is still speculative, it should be noted that data indicat-
ing that the N- and C-terminal halves of Pex5p interact with
each other have already been reported (46). If we assume this
domain arrangement, then the long-range PTS1-induced con-
formational alterations of Pex5p described here and by others
(40, 43) can be rationalized in an easier way. The alternative
would be to consider that binding of a PTS1 cargo protein to
Pex5p also induces conformational alterations in regions of the
Pex5p protein located more than 100 amino acid residues away
as is the case for the Pex13p-binding domain of Pex5p (43). This
possibility, however, is not supported by the observation that
Pex5p-truncated versions lacking the TPR domains are still
good substrates for the peroxisomal docking/translocation ma-
chinery and even for the ATPase catalyzing the export of Pex5p
back into the cytosol (30, 47, 48). Thus, as suggested recently,
it is possible that the peroxisomal targeting domain of Pex5p is
a target of negative regulation exerted by the TPR domains
(30). One prediction of this model is that the TPR domains are
not static structures. Binding of a PTS1-containing protein to
Pex5p should induce significant conformation alterations in
these domains in order to expose the Pex5p peroxisomal tar-
geting domain. We are currently testing this possibility.
To conclude, we would like to note that the protease assay
described here represents an alternative approach to study of
protein-protein interactions involving Pex5p. In contrast to
other in vitro binding assays (e.g. blot overlays or pulldown
experiments), the assay used in this work does not involve a
washing procedure. Thus, if the appropriate negative controls
are included, weak protein-protein interactions (as is probably
the case with the Pex13p-Pex5p interaction) should be detected
with a higher success rate.
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